1,470 results on '"Gershenson, David M."'
Search Results
2. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma
3. Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
4. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
5. Is MEK Inhibitor Therapy the Best Treatment Recommendation for Low-Grade Serous Ovarian Cancer Patients at First Relapse?
6. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study
7. Malignant ovarian germ cell tumors
8. Foreword
9. Contributors
10. Management of Early-Stage Ovarian Cancer
11. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors
12. Clinical and genomic landscape of RAS mutations in gynecologic cancers
13. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors
14. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)
15. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience
16. Malignant diseases of the ovary, fallopian tube, and peritoneum
17. Preface
18. List of contributors
19. Abstract A065: High throughput drug screening to decipher the mechanisms of trametinib adaptive resistance in low-grade serous ovarian cancer cell lines
20. Deciphering the adaptive trametinib resistance in low-grade ovarian serous carcinoma and its translational potential
21. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer.
22. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance
23. Evolving population-based statistics for rare epithelial ovarian cancers
24. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study
25. Low-grade serous ovarian cancer: State of the science
26. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer
27. Uncommon Gynecologic Cancers
28. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors
29. Significance of lymph node ratio on survival of women with borderline ovarian tumors
30. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor
31. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes
32. Accuracy of Intraoperative Frozen Section Diagnosis of Borderline Ovarian Tumors by Hospital Type
33. The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study
34. Low-grade serous ovarian cancer: expert consensus report on the state of the science
35. Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary or Peritoneum
36. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
37. Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)
38. Clinical trial methodology in rare gynecologic tumor research: Strategies for success
39. Survival in Women With Grade 1 Serous Ovarian Carcinoma
40. Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome
41. Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma
42. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
43. Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations
44. DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry
45. FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper
46. Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
47. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study
48. Table S1 from Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors
49. Supplementary Figures 1-6 from Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors
50. Data from Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.